Desmoid tumors are a rare subtype of soft tissue sarcomas that can cause pain, limited mobility and a decreased quality of life, the FDA said. Surgical removal has historically been used to treat these noncancerous tumors, but there is a high risk of it returning.
In a clinical trial of 142 adult patients, study participants received either 150 milligrams of Ogsiveo or a placebo twice a day. Progression-free survival was found in 41% of those taking Ogsiveo and 8% in the placebo group.
The FDA awarded the approval to SpringWorks Therapeutics.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.